Hemofiltrate CC chemokine (HCC)-1 is a recently described human chemokine that is constitutively expressed in numerous tissues and is present at high concentrations in normal plasma. Using a cell line expressing CC chemokine receptor (CCR)5 as a bioassay, we isolated from human hemofiltrate an HCC-1 variant lacking the first eight amino acids. HCC-1[9–74] was a potent agonist of CCR1, CCR3, and CCR5 and promoted calcium flux and chemotaxis of T lymphoblasts, monocytes, and eosinophils. It also blocked entry of HIV-1 strains using CCR5 as coreceptor. Limited tryptic digestion of HCC-1 generated the active variant. Conditioned media from several tumor cell lines activated HCC-1 with a high efficiency, and this activity could be inhibited by serine protease inhibitors. Our results indicate that HCC-1 represents a nonfunctional precursor that can be rapidly converted to the active chemokine by proteolytic processing. This process represents an additional mechanism by which tumor cells might generate chemoattractant molecules and recruit inflammatory cells. It might also affect HIV-1 replication in infected individuals and play an important role in AIDS pathogenesis.
Skip Nav Destination
Article navigation
20 November 2000
Article|
November 20 2000
Natural Proteolytic Processing of Hemofiltrate Cc Chemokine 1 Generates a Potent Cc Chemokine Receptor (Ccr)1 and Ccr5 Agonist with Anti-HIV Properties
Michel Detheux,
Michel Detheux
aFrom Euroscreen S.A., B-1070 Brussels, Belgium
Search for other works by this author on:
Ludger Ständker,
Ludger Ständker
bThe Lower Saxony Institute for Peptide Research (IPF), D-30625 Hannover, Germany
Search for other works by this author on:
Jalal Vakili,
Jalal Vakili
cInstitute of Interdisciplinary Research, Université Libre de Bruxelles, B-1070 Brussels, Belgium
Search for other works by this author on:
Jan Münch,
Jan Münch
dInstitute for Clinical and Molecular Virology, University of Erlangen-Nürnberg, 91054 Erlangen, Germany
Search for other works by this author on:
Ulf Forssmann,
Ulf Forssmann
bThe Lower Saxony Institute for Peptide Research (IPF), D-30625 Hannover, Germany
eDepartment of Urology, Johannes Gutenberg University, 55131 Mainz, Germany
Search for other works by this author on:
Knut Adermann,
Knut Adermann
bThe Lower Saxony Institute for Peptide Research (IPF), D-30625 Hannover, Germany
Search for other works by this author on:
Stefan Pöhlmann,
Stefan Pöhlmann
dInstitute for Clinical and Molecular Virology, University of Erlangen-Nürnberg, 91054 Erlangen, Germany
Search for other works by this author on:
Gilbert Vassart,
Gilbert Vassart
cInstitute of Interdisciplinary Research, Université Libre de Bruxelles, B-1070 Brussels, Belgium
Search for other works by this author on:
Frank Kirchhoff,
Frank Kirchhoff
dInstitute for Clinical and Molecular Virology, University of Erlangen-Nürnberg, 91054 Erlangen, Germany
Search for other works by this author on:
Marc Parmentier,
Marc Parmentier
cInstitute of Interdisciplinary Research, Université Libre de Bruxelles, B-1070 Brussels, Belgium
Search for other works by this author on:
Wolf-Georg Forssmann
Wolf-Georg Forssmann
bThe Lower Saxony Institute for Peptide Research (IPF), D-30625 Hannover, Germany
Search for other works by this author on:
Michel Detheux
aFrom Euroscreen S.A., B-1070 Brussels, Belgium
Ludger Ständker
bThe Lower Saxony Institute for Peptide Research (IPF), D-30625 Hannover, Germany
Jalal Vakili
cInstitute of Interdisciplinary Research, Université Libre de Bruxelles, B-1070 Brussels, Belgium
Jan Münch
dInstitute for Clinical and Molecular Virology, University of Erlangen-Nürnberg, 91054 Erlangen, Germany
Ulf Forssmann
bThe Lower Saxony Institute for Peptide Research (IPF), D-30625 Hannover, Germany
eDepartment of Urology, Johannes Gutenberg University, 55131 Mainz, Germany
Knut Adermann
bThe Lower Saxony Institute for Peptide Research (IPF), D-30625 Hannover, Germany
Stefan Pöhlmann
dInstitute for Clinical and Molecular Virology, University of Erlangen-Nürnberg, 91054 Erlangen, Germany
Gilbert Vassart
cInstitute of Interdisciplinary Research, Université Libre de Bruxelles, B-1070 Brussels, Belgium
Frank Kirchhoff
dInstitute for Clinical and Molecular Virology, University of Erlangen-Nürnberg, 91054 Erlangen, Germany
Marc Parmentier
cInstitute of Interdisciplinary Research, Université Libre de Bruxelles, B-1070 Brussels, Belgium
Wolf-Georg Forssmann
bThe Lower Saxony Institute for Peptide Research (IPF), D-30625 Hannover, Germany
Abbreviations used in this paper: HCC, hemofiltrate CC chemokine; MCP, monocyte chemotactic protein; MIP, macrophage inflammatory protein; RANTES, regulated upon activation, normal T cell expressed and secreted.
M. Detheux, L. Ständker, and J. Vakili contributed equally to this work.
Received:
June 09 2000
Revision Requested:
August 28 2000
Accepted:
September 15 2000
Online ISSN: 1540-9538
Print ISSN: 0022-1007
© 2000 The Rockefeller University Press
2000
The Rockefeller University Press
J Exp Med (2000) 192 (10): 1501–1508.
Article history
Received:
June 09 2000
Revision Requested:
August 28 2000
Accepted:
September 15 2000
Citation
Michel Detheux, Ludger Ständker, Jalal Vakili, Jan Münch, Ulf Forssmann, Knut Adermann, Stefan Pöhlmann, Gilbert Vassart, Frank Kirchhoff, Marc Parmentier, Wolf-Georg Forssmann; Natural Proteolytic Processing of Hemofiltrate Cc Chemokine 1 Generates a Potent Cc Chemokine Receptor (Ccr)1 and Ccr5 Agonist with Anti-HIV Properties. J Exp Med 20 November 2000; 192 (10): 1501–1508. doi: https://doi.org/10.1084/jem.192.10.1501
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement